SG98356A1 - Methods for regulating gastrointestinal motility - Google Patents

Methods for regulating gastrointestinal motility

Info

Publication number
SG98356A1
SG98356A1 SG9607979A SG1996007979A SG98356A1 SG 98356 A1 SG98356 A1 SG 98356A1 SG 9607979 A SG9607979 A SG 9607979A SG 1996007979 A SG1996007979 A SG 1996007979A SG 98356 A1 SG98356 A1 SG 98356A1
Authority
SG
Singapore
Prior art keywords
methods
gastrointestinal motility
regulating gastrointestinal
gastric emptying
motility
Prior art date
Application number
SG9607979A
Other languages
English (en)
Inventor
Orville G Kolterman
Andew A Young
Timothy J Rink
Kathleen Keiting Brown
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Publication of SG98356A1 publication Critical patent/SG98356A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG9607979A 1993-09-07 1994-09-07 Methods for regulating gastrointestinal motility SG98356A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11838193A 1993-09-07 1993-09-07

Publications (1)

Publication Number Publication Date
SG98356A1 true SG98356A1 (en) 2003-09-19

Family

ID=22378228

Family Applications (1)

Application Number Title Priority Date Filing Date
SG9607979A SG98356A1 (en) 1993-09-07 1994-09-07 Methods for regulating gastrointestinal motility

Country Status (23)

Country Link
US (4) US6114304A (fr)
EP (1) EP0717635B1 (fr)
JP (2) JP3821839B2 (fr)
KR (2) KR100391399B1 (fr)
CN (1) CN1134110A (fr)
AT (1) ATE197549T1 (fr)
AU (1) AU7685894A (fr)
BG (1) BG100463A (fr)
BR (1) BR9407424A (fr)
CA (1) CA2171207C (fr)
CZ (1) CZ69596A3 (fr)
DE (1) DE69426304T2 (fr)
DK (1) DK0717635T3 (fr)
ES (1) ES2154299T3 (fr)
GR (1) GR3035387T3 (fr)
HU (1) HUT73490A (fr)
NO (1) NO960899L (fr)
PT (1) PT717635E (fr)
RU (1) RU2177331C2 (fr)
SG (1) SG98356A1 (fr)
SK (1) SK31496A3 (fr)
WO (1) WO1995007098A1 (fr)
ZA (1) ZA946881B (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
RU2177331C2 (ru) * 1993-09-07 2001-12-27 Амилин Фармасьютикалз, Инк. Способы регулирования моторики желудочно-кишечного тракта
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
ES2319936T5 (es) * 1996-08-08 2013-06-24 Amylin Pharmaceuticals, Inc. Regulación de la motilidad gastrointestinal
WO1998030231A1 (fr) 1997-01-07 1998-07-16 Amylin Pharmaceuticals, Inc. Utilisation d'exendines et de leurs agonistes pour reduire la consommation alimentaire
US7101853B2 (en) 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
US6936584B1 (en) 1998-02-13 2005-08-30 Amylin Pharmaceuticals, Inc. Mixed amylin activity compounds
ES2356595T3 (es) * 1998-02-13 2011-04-11 Amylin Pharmaceuticals, Inc. Nuevos compuestos de actividad mixta de la amilina.
ES2343072T3 (es) 1999-01-14 2010-07-22 Amylin Pharmaceuticals, Inc. Exendina para la supresion del glucagon.
CN101181236A (zh) 1999-01-14 2008-05-21 安米林药品公司 新型exendin激动剂制剂及其给药方法
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
ES2440190T3 (es) 2000-03-03 2014-01-28 C. R. Bard, Inc. Dispositivo endoscópico de aposición de tejido con múltiples puertos de succión
ES2435094T3 (es) 2000-05-19 2013-12-18 C.R. Bard, Inc. Dispositivo y método de captura y sutura de tejido
US6451813B1 (en) 2001-01-26 2002-09-17 R. T. Alamo Ventures I, Llc Treatment of gastroparesis in certain patient groups
AU2003273318A1 (en) * 2002-09-12 2004-04-30 University Of Chicago Monitoring and diagnosis of gastric emptying and gastroparesis
WO2004037168A2 (fr) * 2002-10-18 2004-05-06 Amylin Pharmaceuticals, Inc. Traitement de la pancreatite avec de l'amyline
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
WO2004060387A1 (fr) * 2002-12-27 2004-07-22 Diobex, Inc. Compositions et procedes de prevention et reduction de l'hypoglycemie induite par l'insuline
WO2005021026A2 (fr) * 2003-08-29 2005-03-10 Amylin Pharmaceuticals, Inc. Procedes pour traiter ou ameliorer des maladies et des troubles associes a la ghreline
US8114958B2 (en) * 2004-02-11 2012-02-14 Amylin Pharmaceuticals, Inc. Amylin family peptides
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
US8172857B2 (en) 2004-08-27 2012-05-08 Davol, Inc. Endoscopic tissue apposition device and method of use
US20090156474A1 (en) 2004-11-01 2009-06-18 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
AU2006230420B2 (en) 2005-03-31 2011-11-24 Amylin Pharmaceuticals, Llc Compositions and methods for the control, prevention, and treatment of obesity and eating disorders
US20090054305A1 (en) 2006-03-15 2009-02-26 Novo Nordisk A/S Mixtures of Amylin and Insulin
WO2007112069A2 (fr) * 2006-03-23 2007-10-04 Amylin Pharmaceuticals, Inc. Endothéline et agonistes des récepteurs de l'endothéline pour le traitement de maladies métaboliques
US20090181890A1 (en) * 2006-03-31 2009-07-16 Amylin Pharmaceuticals , Inc. Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders
WO2008097536A2 (fr) 2007-02-05 2008-08-14 Amylin Pharmaceuticals, Inc. Compositions et méthodes de traitement de maladies et troubles psychiatriques
MX2010005345A (es) * 2007-11-14 2010-08-31 Amylin Pharmaceuticals Inc Metodos para el tratamiento de la obesidad y enfermedades y trastornos relacionados con la obesidad.
EP2405934B1 (fr) 2009-03-12 2014-03-26 Nordic Bioscience A/S Traitement du diabète et du syndrome métabolique
US8748375B2 (en) * 2009-03-17 2014-06-10 Amylin Pharmaceuticals, Llc Methods for affecting body composition using amylin agonists
CN107129538B (zh) 2010-04-27 2021-07-16 西兰制药公司 Glp-1受体激动剂和胃泌素的肽缀合物及其用途
WO2013064669A1 (fr) 2011-11-03 2013-05-10 Zealand Pharma A/S Conjugués de peptide agoniste du récepteur du glp-1 et de gastrine
CN104662038B (zh) 2012-07-23 2018-11-06 西兰制药公司 胰高血糖素类似物
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
CN105745222A (zh) 2013-10-17 2016-07-06 西兰制药公司 酰化胰高血糖素类似物
CA2929107C (fr) 2013-11-06 2023-09-26 Zealand Pharma A/S Composes agonistes triples glucagon-glp-1-gip
TWI670281B (zh) 2013-11-06 2019-09-01 西蘭製藥公司 Ｇｉｐ－ｇｌｐ－１雙重促效劑化合物及方法
US9656017B2 (en) 2014-06-20 2017-05-23 Howard E. Greene Infusion delivery devices and methods
ES2883345T3 (es) 2014-10-29 2021-12-07 Zealand Pharma As Compuestos agonistas del GIP y métodos
MX2017011182A (es) 2015-03-18 2018-06-06 Zealand Pharma As Analogos de amilina.
JP6989385B2 (ja) 2015-04-16 2022-01-05 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
BR112019010624A2 (pt) 2016-12-09 2019-10-22 Zealand Pharma As agonistas duplos de glp-1/glp-2 acilados e composição
CN110366424B (zh) 2016-12-27 2024-05-24 阿道恰公司 包含胰淀素、胰淀素受体激动剂或胰淀素类似物和共聚氨基酸的可注射水溶液形式的组合物
PL3658115T4 (pl) 2017-07-27 2022-08-08 Adocia Kompozycje w postaci wodnego roztworu do wstrzykiwań zawierające co najmniej insulinę ludzką a21g i co najmniej jeden supresor glukagonu o działaniu prandialnym
FR3083086A1 (fr) 2018-06-29 2020-01-03 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
WO2019110788A1 (fr) 2017-12-07 2019-06-13 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3083085B1 (fr) 2018-06-29 2020-10-02 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
CN111683674A (zh) 2017-12-07 2020-09-18 阿道恰公司 包含胰淀素、胰淀素激动剂受体或胰淀素类似物和共聚氨基酸的可注射水溶液形式的组合物
WO2019110797A1 (fr) 2017-12-07 2019-06-13 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
WO2019115411A1 (fr) 2017-12-07 2019-06-20 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3084586B1 (fr) 2018-08-03 2020-11-06 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530838A (en) * 1983-07-08 1985-07-23 The Salk Institute For Biological Studies Synthetic calcitonin-gene-related peptides for lowering blood pressure or gastric acid secretion in mammals
US5175145A (en) * 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451394A (en) * 1982-10-25 1984-05-29 American Home Products Corporation Dodecapeptides preventing glucose and triglyceride assimilation
US4690486A (en) * 1985-04-29 1987-09-01 Texas Instruments Incorporated Four position interlacing apparatus
GB8709871D0 (en) * 1987-04-27 1987-06-03 Turner R C Peptides
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
US5367052A (en) * 1987-04-27 1994-11-22 Amylin Pharmaceuticals, Inc. Amylin peptides
US5266561A (en) * 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
US5166192A (en) 1989-05-09 1992-11-24 Mathias John R Treatment of motility disorders with a GnRH analog
US5260275A (en) * 1990-08-14 1993-11-09 Amylin Pharmaceuticals, Inc. Hypoglycemics
US5187154A (en) * 1990-12-13 1993-02-16 Board Of Regents, The University Of Texas System Diagnosis and treatment of humans with diabetes or at risk to develop diabetes
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
US5264372A (en) * 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
ATE157010T1 (de) * 1991-05-24 1997-09-15 Amylin Pharmaceuticals Inc Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
US5580953A (en) * 1991-08-14 1996-12-03 Amylin Pharmaceuticals, Inc. Amylin antagonist peptides and uses therefor
DK0567626T3 (da) * 1991-11-19 2001-12-17 Amylin Pharmaceuticals Inc Amylin-agonist-peptider og anvendelse deraf
US5376638A (en) * 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
WO1994020116A1 (fr) * 1993-03-10 1994-09-15 University Of Alabama Research Foundation Amorces artificielles pour la synthese du glycogene
RU2177331C2 (ru) * 1993-09-07 2001-12-27 Амилин Фармасьютикалз, Инк. Способы регулирования моторики желудочно-кишечного тракта
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530838A (en) * 1983-07-08 1985-07-23 The Salk Institute For Biological Studies Synthetic calcitonin-gene-related peptides for lowering blood pressure or gastric acid secretion in mammals
US5175145A (en) * 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists

Also Published As

Publication number Publication date
BG100463A (en) 1997-03-31
US6114304A (en) 2000-09-05
JPH09502443A (ja) 1997-03-11
AU7685894A (en) 1995-03-27
NO960899D0 (no) 1996-03-06
HU9600558D0 (en) 1996-05-28
KR20040004418A (ko) 2004-01-13
SK31496A3 (en) 1998-06-03
ATE197549T1 (de) 2000-12-15
WO1995007098A1 (fr) 1995-03-16
US20040097415A1 (en) 2004-05-20
JP3821839B2 (ja) 2006-09-13
EP0717635B1 (fr) 2000-11-15
NO960899L (no) 1996-05-06
CA2171207A1 (fr) 1995-03-16
CZ69596A3 (en) 1997-06-11
US7407934B2 (en) 2008-08-05
KR100391399B1 (ko) 2004-02-11
ES2154299T3 (es) 2001-04-01
BR9407424A (pt) 1996-04-09
ZA946881B (en) 1995-10-30
HUT73490A (en) 1996-08-28
DE69426304T2 (de) 2001-03-15
CN1134110A (zh) 1996-10-23
CA2171207C (fr) 2010-03-30
US6608029B1 (en) 2003-08-19
GR3035387T3 (en) 2001-05-31
KR100429966B1 (ko) 2004-05-04
US5795861A (en) 1998-08-18
PT717635E (pt) 2001-04-30
EP0717635A1 (fr) 1996-06-26
JP2004331674A (ja) 2004-11-25
DK0717635T3 (da) 2000-12-11
RU2177331C2 (ru) 2001-12-27
DE69426304D1 (de) 2000-12-21

Similar Documents

Publication Publication Date Title
GR3035387T3 (en) Methods for regulating gastrointestinal motility
CA2262647A1 (fr) Methodes de regulation de la motilite gastro-intestinale
CA2257077A1 (fr) Traitement contre la diarrhee
CA2274596A1 (fr) Compositions et procedes servant a ameliorer le fonctionnement gastro-intestinal
EP1618898A3 (fr) Procédure de régulation de l' angiogenèse
IL111734A0 (en) Compositions for the preparation of in vivo therapeutic products
CY1107752T1 (el) Xρηση των εξενδινων και αγωνιστων τους για τη θεραπεια του σακχαρωδους διαβητη της κυησης
MY132189A (en) Recombinant obese (ob) proteins
PL346520A1 (en) Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
IL112373A0 (en) Use of interleukin-12 to prevent graft versus host disease
LT2002063A (en) Low-dose metformin and gliburide combinations for treating diabetes
DE69920885D1 (en) C-myc-bindendes protein "c-myc coding region determinant-binding protein (crd-bp)"
GR3031250T3 (en) Methods of diagnosing and treating preeclampsia
CA2340320A1 (fr) Traitement d'angiopathies microvasculaires
HK1047707A1 (zh) (+)-曲馬朵、o-去甲曲馬朵或(+)-o-去甲曲馬朵、o-去甲-n-單-去甲-曲馬朵或(+)-o-去甲-n-單-去甲-曲馬朵治療尿失禁的用途
UA50761C2 (uk) Спосіб запобігання та/або лікування серцевих захворювань, фармацевтична композиція та спосіб запобігання та/або лікування серцевої недостатності та дисфункції шлуночків в організмі теплокровної тварини
WO1999059628A3 (fr) Therapie combinee pour le traitement de tumeurs
WO1992018536A3 (fr) Procede de detection et de localisation de tissus comprenant des recepteurs de neurokinine 1
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
AU6648200A (en) Method and composition for preventing or treating adverse physiological effects associated with cardiac disease
PT979098E (pt) Metodo para o tratamento da hiperprolactinemia e de prolactinomas
ES8500951A1 (es) Un procedimiento para preparar 6-metil-tio-espiro-ckroman-4,4' imidazolin-2',5'-diona.
GEU2000631Y (en) Method for Selective-Proximal Vagotomy
UA29280A (uk) Спосіб лікування флегмони шлунку
UA23123A (uk) Спосіб хірургічhого лікуваhhя hавколососочкових виразок дваhадцятипалої кишки